Department of Nephrology, Dialysis and Renal Transplantation, A. Manzoni Hospital, Lecco, Italy.
Nephron Clin Pract. 2010;115(1):c82-9. doi: 10.1159/000294281. Epub 2010 Mar 8.
Oxidative stress, a recently identified factor related to the response to erythropoiesis-stimulating agents (ESAs), is increased in hemodialysis patients. The aim of this study was to verify whether ESA responsiveness improves if the anti-oxidant vitamin E (Vi-E) is placed on the blood-side layer of a synthetic polysulfone (PS) dialyzer.
This 8-month, controlled and open randomized study involved 2 groups of patients on stable ESA therapy undergoing hemodialysis using a PS dialyzer with or without Vi-E treatment. Hemoglobin, albumin, high-sensitivity C-reactive protein, interleukin-6, iron status, parathyroid hormone (PTH), Vi-E (alpha- and gamma-tocopherol levels) and the oxidative stress markers, advanced oxidation protein products, carbonyls and advanced glycation end products were evaluated every 2 months. The primary outcome measure was ESA resistance, the weekly ESA dose divided by the product between hemoglobin level and end-dialysis body weight.
Nineteen of the 20 randomized patients completed the study. During the follow-up, the ESA resistance significantly decreased (p = 0.024), greater in the Vi-E group (37%) than in the PS group (20%), but this difference was not statistically significant (p = 0.596). Baseline PTH and Vi-E levels were associated with ESA resistance. In the secondary analysis, including these covariates in the model, the difference between groups in ESA resistance became significant (p = 0.042).
Vi-E placed on the blood-side of a dialyzer may have a possible beneficial effect on ESA resistance in hemodialysis patients; baseline PTH levels seem to predict ESA resistance and were useful in showing the possible beneficial effect of Vi-E and should be considered in designing adequate-sized trials for testing this hypothesis.
氧化应激是一种与促红细胞生成素刺激剂(ESAs)反应相关的新发现的因素,在血液透析患者中增加。本研究的目的是验证如果将抗氧化维生素 E(Vi-E)置于合成聚砜(PS)透析器的血液侧层,ESA 的反应性是否会改善。
这是一项为期 8 个月的对照、开放随机研究,涉及两组接受 PS 透析器稳定 ESA 治疗的患者,分别采用或不采用 Vi-E 治疗。每 2 个月评估血红蛋白、白蛋白、高敏 C 反应蛋白、白细胞介素 6、铁状态、甲状旁腺激素(PTH)、Vi-E(α-和γ-生育酚水平)和氧化应激标志物、晚期氧化蛋白产物、羰基和晚期糖基化终产物。主要观察指标为 ESA 抵抗,每周 ESA 剂量除以血红蛋白水平与终末期透析体重的乘积。
20 名随机患者中有 19 名完成了研究。在随访期间,ESA 抵抗显著降低(p = 0.024),Vi-E 组(37%)大于 PS 组(20%),但差异无统计学意义(p = 0.596)。基线 PTH 和 Vi-E 水平与 ESA 抵抗相关。在二次分析中,将这些协变量纳入模型后,组间 ESA 抵抗的差异具有统计学意义(p = 0.042)。
将 Vi-E 置于透析器的血液侧可能对血液透析患者的 ESA 抵抗具有潜在的有益作用;基线 PTH 水平似乎可预测 ESA 抵抗,并有助于显示 Vi-E 的可能有益作用,在设计足够大的试验以检验这一假说时应考虑这些因素。